Patient characteristics
Variables . | Data . |
|---|---|
| Total no. patients | 607 |
| Mean age, y (range) | 36.6 (1-65) |
| Sex, no. (%) | |
| Men | 322 (53) |
| Women | 285 (47) |
| Disease and disease stage at transplantation, no. (%) | |
| Acute myelogenous leukemia | 146 (24) |
| First complete remission | 84 (14) |
| Second complete remission | 33 (5) |
| Other | 29 (5) |
| Acute lymphoblastic leukemia | 98 (16) |
| First complete remission | 35 (6) |
| Second or more complete remission | 35 (6) |
| Other | 28 (4) |
| Chronic myelogenous leukemia | 180 (30) |
| First chronic phase | 122 (20) |
| Second chronic phase | 10 (2) |
| Accelerated phase | 28 (4) |
| Other | 20 (3) |
| Myelodysplastic syndrome | 60 (10) |
| Non-Hodgkin lymphoma | 44 (7) |
| First complete remission | 2 (<1) |
| Second or more remission | 10 (2) |
| Other | 27 (4) |
| Aplastic anemia | 36 (6) |
| Other diseases | 43 (7) |
| Conditioning regimens, no. (%) | |
| TBI and Cy | 280 (46) |
| TBI and Cy and other | 108 (18) |
| Bu and Cy | 94 (15) |
| Cy with or without other | 20 (3) |
| Bu and other(s) | 39 (6) |
| TBI and other | 54 (9) |
| Other | 12 (2) |
| GVHD prophylaxis, no. (%) | |
| CsA and MTX with or without ATG | 607 |
| Graft type | |
| Bone marrow | 569 (93) |
| Peripheral blood | 36 (6) |
| Donor type, no. (%) | |
| Matched unrelated | 137 (23) |
| Matched related | 419 (69) |
| Mismatched unrelated | 35 (6) |
| Mismatched related | 14 (2) |
| Unknown/missing | 2 (<1) |
| Donor/recipient CMV status, no. (%) | |
| −/− | 129 (21) |
| −/+ | 63 (10) |
| +/− | 51 (8) |
| +/+ | 87 (14) |
| Not reported | 277 (26) |
| Median interval from diagnosis to transplantation, d (range) | 239 (33-13 082) |
Variables . | Data . |
|---|---|
| Total no. patients | 607 |
| Mean age, y (range) | 36.6 (1-65) |
| Sex, no. (%) | |
| Men | 322 (53) |
| Women | 285 (47) |
| Disease and disease stage at transplantation, no. (%) | |
| Acute myelogenous leukemia | 146 (24) |
| First complete remission | 84 (14) |
| Second complete remission | 33 (5) |
| Other | 29 (5) |
| Acute lymphoblastic leukemia | 98 (16) |
| First complete remission | 35 (6) |
| Second or more complete remission | 35 (6) |
| Other | 28 (4) |
| Chronic myelogenous leukemia | 180 (30) |
| First chronic phase | 122 (20) |
| Second chronic phase | 10 (2) |
| Accelerated phase | 28 (4) |
| Other | 20 (3) |
| Myelodysplastic syndrome | 60 (10) |
| Non-Hodgkin lymphoma | 44 (7) |
| First complete remission | 2 (<1) |
| Second or more remission | 10 (2) |
| Other | 27 (4) |
| Aplastic anemia | 36 (6) |
| Other diseases | 43 (7) |
| Conditioning regimens, no. (%) | |
| TBI and Cy | 280 (46) |
| TBI and Cy and other | 108 (18) |
| Bu and Cy | 94 (15) |
| Cy with or without other | 20 (3) |
| Bu and other(s) | 39 (6) |
| TBI and other | 54 (9) |
| Other | 12 (2) |
| GVHD prophylaxis, no. (%) | |
| CsA and MTX with or without ATG | 607 |
| Graft type | |
| Bone marrow | 569 (93) |
| Peripheral blood | 36 (6) |
| Donor type, no. (%) | |
| Matched unrelated | 137 (23) |
| Matched related | 419 (69) |
| Mismatched unrelated | 35 (6) |
| Mismatched related | 14 (2) |
| Unknown/missing | 2 (<1) |
| Donor/recipient CMV status, no. (%) | |
| −/− | 129 (21) |
| −/+ | 63 (10) |
| +/− | 51 (8) |
| +/+ | 87 (14) |
| Not reported | 277 (26) |
| Median interval from diagnosis to transplantation, d (range) | 239 (33-13 082) |
TBI indicates total body irradiation; Cy, cyclophosphamide; Bu, busulfan; CsA, cyclosporin A; MTX, methotrexate; ATG, antithymocyte globulin; CMV, cytomegalovirus.